The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail


30 milligram(s) Solution for infusion in pre-filled syringe

AstraZeneca ABEU/1/17/1252/001

Main Information

Trade NameFasenra
Active SubstancesBenralizumab
Strength30 milligram(s)
Dosage FormSolution for infusion in pre-filled syringe
Licence HolderAstraZeneca AB
Licence NumberEU/1/17/1252/001

Group Information

ATC CodeR03DX Other systemic drugs for obstructive airway diseases
R03DX10 benralizumab


Licence Issued
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Marketing StatusUnknown


Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back